STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Fusion Pharmaceuticals to Present at the Jefferies Virtual London Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company, will present at the Jefferies Virtual London Healthcare Conference on November 19, 2020, at 8:30 AM EST. The presentation will feature CEO John Valliant, CFO John Crowley, and CMO James O'Leary. Attendees can access a live webcast on the company's website, with a replay available for 90 days. Fusion focuses on developing next-generation radiopharmaceuticals, using its proprietary Fast-Clear linker technology to target tumors selectively. The lead program, FPI-1434, is currently undergoing a Phase 1 clinical trial.

Positive
  • None.
Negative
  • None.

Insights

Analyzing...

HAMILTON, Ontario and BOSTON, Nov. 12, 2020 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will participate in a "fireside chat" presentation at the Jefferies Virtual London Healthcare Conference on Thursday, November 19, 2020 at 8:30am EST / 1:30pm GMT. Presenting on behalf of Fusion will be Chief Executive Officer John Valliant, Ph.D., Chief Financial Officer John Crowley, and Chief Medical Officer James O'Leary, M.D.

A live webcast of the event will be available on the "Events and Presentations" page in the "Investors and Media" section of the Company's website at https://ir.fusionpharma.com/events-webcasts. A replay of the webcast will be archived on the Company's website for 90 days following the presentation.  

About Fusion
Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Employing a proprietary Fast-Clear linker technology, Fusion connects alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha emitting payloads to tumors. Fusion's lead program, FPI-1434, is currently in a Phase 1 clinical trial.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/fusion-pharmaceuticals-to-present-at-the-jefferies-virtual-london-healthcare-conference-301172266.html

SOURCE Fusion Pharmaceuticals Inc.

FAQ

When is Fusion Pharmaceuticals presenting at the Jefferies Virtual London Healthcare Conference?

Fusion Pharmaceuticals is presenting on November 19, 2020, at 8:30 AM EST.

Who will represent Fusion Pharmaceuticals at the conference?

CEO John Valliant, CFO John Crowley, and CMO James O'Leary will represent Fusion Pharmaceuticals.

Where can I watch the Fusion Pharmaceuticals conference presentation?

The presentation can be accessed via a live webcast on the company's website under the 'Events and Presentations' section.

What is the focus of Fusion Pharmaceuticals' development?

Fusion Pharmaceuticals focuses on developing next-generation radiopharmaceuticals as precision medicines.

What is Fusion Pharmaceuticals' lead program?

The lead program of Fusion Pharmaceuticals is FPI-1434, which is in a Phase 1 clinical trial.
Fusion Pharmaceuticals Inc.

NASDAQ:FUSN

FUSN Rankings

FUSN Latest News

FUSN Stock Data

1.83B
75.27M
Biological Product (except Diagnostic) Manufacturing
Biological Products, (no Disgnostic Substances)
Link
CA
HAMILTON